The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-t alone in patients with metastatic castrate resistant prostate cancer.
 
Przemyslaw Twardowski
Stock and Other Ownership Interests - Exelixis
Honoraria - Bayer (I); Dendreon; Janssen; Medivation/Astellas; Roche; Sanofi
Consulting or Advisory Role - Roche
Speakers' Bureau - Bayer; Dendreon; Janssen; Medivation/Astellas; Roche; Sanofi
Research Funding - Dendreon
 
Jeffrey Y.C. Wong
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Paul Henry Frankel
No Relationships to Disclose
 
Kelly Franklin
No Relationships to Disclose
 
Maribel Junqueira
No Relationships to Disclose
 
Manisha R. Prajapati
No Relationships to Disclose
 
Deborah Harwood
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)